A clinical trial agreement (CTA) is the legally binding contract that fixes how a trial will run, who pays for what, who owns any resulting intellectual property, and who carries liability if something goes wrong. It is negotiated between the sponsor (or its contract research organisation) and the research site, and it must be fully executed before the first participant is recruited.
A clinical trial agreement is the contract that allocates the legal, financial and operational responsibilities for conducting a specific clinical study between a sponsor and a research institution or investigator. Research administrators new to clinical contracting encounter the CTA as the single document that everything else — costings, indemnity cover, publication clearance, data ownership — hangs off.
- What is a clinical trial agreement?
- Who are the parties to a clinical trial agreement?
- What clauses does a clinical trial agreement cover?
- Commercial CTA or non-commercial agreement — which applies?
- How is a CTA negotiated and signed off?
- Common questions on clinical trial agreements
- What this means for research administrators
What is a clinical trial agreement?
A clinical trial agreement is a written contract, not a protocol or an ethics approval. It sits alongside — but is legally distinct from — the study protocol, the participant information sheet, and any regulatory or ethics sign-off. Its function is purely contractual: it converts the scientific plan for a trial into binding obligations that a court could enforce.
Every jurisdiction that runs interventional trials of medicinal products requires one. In the UK, a CTA (or its non-commercial equivalent) must be in place before a site can open to recruitment under the UK Clinical Trials Regulations, and the Health Research Authority treats a missing or incomplete agreement as a start-up blocker, not a formality to be finished later.
Who are the parties to a clinical trial agreement?
Most CTAs involve three or four distinct parties, each with a different legal interest in the trial. The sponsor initiates, funds and takes overall responsibility for the trial; the research site (a hospital, university, or NHS trust) hosts the study and employs the staff who run it; and the principal investigator is the named clinician or academic accountable for day-to-day conduct at that site.
- Sponsor — a pharmaceutical, biotech or medical device company, or an academic institution acting as sponsor for investigator-led research.
- Contract research organisation (CRO) — frequently contracted by the sponsor to manage set-up, monitoring and payments; in tripartite UK model agreements, the CRO can be a direct signatory alongside the sponsor and the site.
- Research site / host institution — the legal entity (NHS trust, university, or independent hospital) that signs on behalf of the department running the study.
- Principal investigator — named in the agreement but usually not a contracting party in their personal capacity; their obligations run through their employing institution.
The CITI Program summarises the arrangement precisely: a CTA “serves as a legally binding contract between a sponsor, site, and researcher, and outlines each party’s responsibilities and obligations for the clinical trial.”
What clauses does a clinical trial agreement cover?
A CTA is built from a fixed set of recurring clauses, and administrators new to the process should expect negotiation to concentrate almost entirely on four of them: indemnity, intellectual property, publication rights, and data/record access. The rest are usually more mechanical.
| Clause | What it fixes | Typical friction point |
|---|---|---|
| Indemnity and insurance | Who compensates whom for harm, negligence, or breach | Sponsor indemnity wording vs institutional NHS indemnity schemes |
| Intellectual property | Ownership of background IP vs new inventions arising from the trial | Background IP retained by originating party; foreground IP terms vary by contract type |
| Publication rights | When and how results may be published or presented | Sponsor review period vs researcher’s right to publish negative results |
| Confidentiality | Protection of proprietary protocols, data and trial materials | Duration of confidentiality obligations after trial closure |
| Financial terms | Budget, payment schedule, and cost recovery | Per-patient costs vs milestone-linked payment triggers |
| Data and record-keeping | Access, retention and audit rights over trial records | Regulatory retention periods vs institutional data-governance policy |
| Subject injury | Care and compensation for participants harmed by the trial | Allocation of liability between sponsor and clinical negligence cover |
Peer-reviewed research backs up why these clauses matter operationally, not just legally: a quantitative study published via Cambridge Core (Lawrence et al.) found that standardised agreement templates measurably reduce multisite trial start-up time compared with bespoke, clause-by-clause negotiation.
Commercial CTA or non-commercial agreement — which applies?
Which template an administrator reaches for depends on who is funding the trial, not on the disease area or design. This distinction is UK-specific but the underlying logic — industry-funded work uses a different contracting route to grant-funded academic work — recurs across most national research systems.
| Feature | Model Clinical Trial Agreement (mCTA) | Model Non-Commercial Agreement (mNCA) |
|---|---|---|
| Funder | Pharmaceutical, biotech or device company | Grant body, charity, or NIHR/UKRI funding |
| Publisher | ABPI / HRA UK-wide model suite | UK-wide non-commercial model agreement suite |
| IP default position | Sponsor typically retains foreground IP | Host institution typically retains IP |
| Common signatories | Sponsor, CRO, NHS trust | Funder, NHS trust, sometimes co-sponsoring university |
The Health Research Authority confirmed on 28 April 2026 that it had issued an updated suite of UK model agreements to reflect changes to the UK Clinical Trials Regulations, covering both commercial and non-commercial templates. The NIHR confirms that model agreements are one of the UK-wide tools institutions use alongside the National Contract Value Review when setting per-patient trial costs. The Association of the British Pharmaceutical Industry separately maintains a tripartite Model Generic Clinical Trial Agreement for industry-sponsored research delivered through NHS hospitals and managed by CROs.
How is a CTA negotiated and signed off?
Sign-off follows a predictable sequence: the sponsor or CRO issues a draft (usually a model agreement where one applies), the institution’s research and innovation office reviews it against institutional policy, legal counsel on both sides negotiate the contested clauses, and the agreement is executed by an authorised signatory at the institution — rarely the investigator personally.
- Draft issued, typically based on a national model template where the funder type allows it.
- Institutional review against local indemnity, IP and data-governance policy.
- Negotiation of contested clauses — indemnity and publication rights are the most common sticking points.
- Legal execution by the institution’s authorised signatory, not the principal investigator.
- Filing alongside ethics approval and regulatory documentation before site activation.
Using an unamended model agreement removes most of this negotiation entirely, which is precisely why the HRA and NIHR continue to maintain and update the UK-wide model suite rather than leaving every trial to bespoke drafting.
Common questions on clinical trial agreements
What is a clinical trials agreement?
A clinical trials agreement is a legally binding contract between a sponsor, a research site and an investigator that fixes each party’s responsibilities before a study begins. It covers funding, indemnity, intellectual property, publication rights and data access, and must be executed before recruitment starts.
What is the difference between a CTA and a CRA?
A CTA (clinical trial agreement) is the contract governing a study; a CRA (clinical research associate) is a person who monitors trial conduct and compliance at sites. One is a legal document; the other is a job role responsible for oversight and monitoring within the trial.
Who develops the clinical trial agreement?
The sponsor or its CRO typically issues the first draft, often a national model agreement where one is available for the funding type. The host institution’s research office and legal counsel then negotiate amendments before an authorised institutional signatory executes the final version.
What this means for research administrators
The direction of travel in the UK is towards standardisation, not bespoke drafting. The HRA’s April 2026 update to the model agreement suite, and the NIHR’s continued linkage of model contracts to the National Contract Value Review, push institutions towards unamended templates as the default and bespoke drafting as the justified exception.
The practical takeaway: identify the funding type first — commercial sponsor versus non-commercial funder — before selecting a template, route indemnity and publication-rights clauses to legal review early, and treat the CTA as a live governance document, filed and retrievable alongside ethics approval for the trial’s life, not a one-off signing formality.
The CTA sits within a wider set of research administration obligations spanning ethics, finance and compliance sign-off — treating it in isolation from that broader governance process is the most common source of late-stage delay.
